- Elexacaftor/tezacaftor/ivacaftor, sold
under the
brand names Trikafta and
Kaftrio, is a fixed-dose
combination medication used to
treat cystic fibrosis....
- 2020,
Vertex and NHS
expanded the
agreement to
include reimbur****t of
Kaftrio (the name used for
marketing Trikafta in the UK),
making England one of...
- in 2019. The fixed-dose
combination elexacaftor/tezacaftor/ivacaftor (
Kaftrio) was
approved for
medical use in the
European Union in
August 2020, for...
- the age of 6. In
Europe this drug was
approved in 2020 and
marketed as
Kaftrio. It is used in
those that have a f508del mutation,
which occurs in about...
-
publication of
final draft NICE
guidance recommending use of the
drugs Kaftrio,
Orkambi and
Symkevi for
cystic fibrosis.
Nesbitt praised local health...
- Excellence, (NICE) said in its
final draft guidance that Orkambi, Symkevi, and
Kaftrio are
recommended for the
treatment of
Cystic Fibrosis, with
Vertex coming...
